$0.56
(Market cap
$1,666 Mln
Revenue (TTM)
$232 Mln
P/E Ratio
--
P/B Ratio
133.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
24.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.1
-
Face value
--
-
Shares outstanding
29,608,481
10 Years Aggregate
CFO
$-396.03 Mln
EBITDA
$-503.83 Mln
Net Profit
$-564.65 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
AnaptysBio (ANAB)
| 72.8 | 4.6 | 5.1 | 312.0 | 62.0 | 26.4 | -- |
|
BSE Sensex*
| -9.3 | -1.7 | 2.8 | -4.2 | 5.5 | 5.8 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
AnaptysBio (ANAB)
| 266.2 | -37.9 | -30.9 | -10.8 | 61.6 | 32.3 | -74.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
AnaptysBio (ANAB)
|
55.8 | 1,666.4 | 232.4 | -26.8 | 24.1 | -- | -- | 133.3 |
| 85.4 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 267.3 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 71.9 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 58.5 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 109.7 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 369.2 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 546.9 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 593.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 357.5 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout AnaptysBio (ANAB)
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete... which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California. Read more
-
President, CEO & Director
Mr. Daniel R. Faga
-
President, CEO & Director
Mr. Daniel R. Faga
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for AnaptysBio (ANAB)
What is the current share price of AnaptysBio Inc (ANAB) Today?
The share price of AnaptysBio Inc (ANAB) is $55.84 (NASDAQ) as of 02-Sep-2026 16:00 EDT. AnaptysBio Inc (ANAB) has given a return of 62% in the last 3 years.
What is the current PB & PE ratio of AnaptysBio Inc (ANAB)?
Since, TTM earnings of AnaptysBio Inc (ANAB) is negative, P/E ratio is not available.
The P/B ratio of AnaptysBio Inc (ANAB) is 133.30 times as on 28-Aug-2026, a 2473 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-114.84 |
40.84 |
2024 |
-2.78 |
5.69 |
2023 |
-3.48 |
6.46 |
2022 |
-6.85 |
3.36 |
2021 |
-16.55 |
2.68 |
What is the 52 Week High and Low of AnaptysBio Inc (ANAB)?
The 52-week high and low of AnaptysBio Inc (ANAB) are Rs 72.36 and Rs 11.40 as of 03-Sep-2026.
What is the market cap of AnaptysBio Inc (ANAB)?
AnaptysBio Inc (ANAB) has a market capitalisation of $ 1,666 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in AnaptysBio Inc (ANAB)?
Before investing in AnaptysBio Inc (ANAB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.